Kelly Nash, APRN
Family · San Antonio, TXNPI 1568059582
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $664 of the $763 with a category attached, or 87.0%. It is spread thinly across 16 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $360, 2.9 times the $123 reported in 2022.
Across 26 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$122
- Exelixis Inc.$99
- Takeda Pharmaceuticals U.S.A., Inc.$88
- Genentech USA, Inc.$80
- Eisai Inc.$68
- AstraZeneca$49
- plus $257 from 10 others
What the payments were for
- Food & beverage$66487%
- Education$9913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Exelixis Inc. | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Genentech USA, Inc. | 3 | $80 |
| Eisai Inc. | 3 | $68 |
| AstraZeneca | 2 | $49 |
| Bristol Myers Squibb | 2 | $47 |
| AbbVie | 2 | $46 |
| Argenx US, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Pharmaand GmbH | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$122
How this compares
$763 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 20 | $391 |
| Prochlorperazine Maleate | 12 | $101 |
| Ondansetron Hcl | 13 | $92 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.